A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia

Ibrutinib is highly efficacious and used at 420 mg/d for treatment of chronic lymphocytic leukemia (CLL). We previously demonstrated a decline in Bruton’s tyrosine kinase (BTK) protein levels in CLL cells after 1 cycle of ibrutinib, suggesting ibrutinib dose could be lowered after the first cycle wi...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Blood
Prif Awduron: Chen, Lisa S., Bose, Prithviraj, Cruz, Nichole D., Jiang, Yongying, Wu, Qi, Thompson, Philip A., Feng, Shuju, Kroll, Michael H., Qiao, Wei, Huang, Xuelin, Jain, Nitin, Wierda, William G., Keating, Michael J., Gandhi, Varsha
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Hematology 2018
Pynciau:
Clinical Trials and Observations
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6251009/
https://ncbi.nlm.nih.gov/pubmed/30254130
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-06-860593
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg